21.4  1 (4.9%)		04-06 10:34
Open: 20.4 High: 21.4 Volume: 3,484		Pre. Close: 20.4 Low: 20.01 Market Cap: 14(M)

Short term
Mid term
Targets	6-month :	30.02	1-year :	34.16
Resists	First :	25.7	Second :	29.25
Pivot price	22.06
Supports	First :	19.97	Second :	16.61
MAs	MA(5) :	20.94	MA(20) :	22.51
	MA(100) :	25.02	MA(250) :	22.39
MACD	MACD :	-0.7	Signal :	-0.5
%K %D	K(14,3) :	10.7	D(3) :	12.4
RSI	RSI(14): 40.8
52-week	High :	54.29	Low :	9

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ PTHS ] has closed above bottom band by 15.5%. Bollinger Bands are 33% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	21.37 - 21.5	21.5 - 21.61
Low:	20.13 - 20.26	20.26 - 20.37
Close:	20.21 - 20.42	20.42 - 20.61

Pelthos Therapeutics Inc., a bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens. The company offers ZELSUVMI for the treatment of molluscum contagiosum in adults and children 1 year of age and older. It also provides NITRICIL, a proprietary nitric oxide-based technology platform. The company was formerly known as Channel Therapeutics Corporation and changed its name to Pelthos Therapeutics Inc. in July 2025. Pelthos Therapeutics Inc. was founded in 2002 and is based in Durham, North Carolina.

Wed, 01 Apr 2026
Board member Todd Davis (PTHS) updates Pelthos stock grants and holdings - Stock Titan

Wed, 01 Apr 2026
Board member Richard Malamut logs revised RSU stock awards at Pelthos (PTHS) - Stock Titan

Wed, 01 Apr 2026
Director Greenleaf (PTHS) awarded 25,478 Pelthos Therapeutics RSUs - Stock Titan

Wed, 01 Apr 2026
Director Matthew Pauls receives 25,478-share RSU grant at Pelthos (PTHS) - Stock Titan

Thu, 19 Mar 2026
Earnings call transcript: Pelthos Therapeutics Q4 2025 misses EPS forecast, stable stock - Investing.com

Thu, 19 Mar 2026
Pelthos Therapeutics 2025 10-K: $16.8M Revenue, $(23.04) EPS - TradingView

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Neutral
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: AMEX
Sector: Healthcare
Industry: Biotechnology
Shares Out	0 (M)
Shares Float	0 (M)
Held by Insiders	0 (%)
Held by Institutions	0 (%)
Shares Short	0 (K)
Shares Short P.Month	0 (K)

EPS	0
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	0 %
Return on Equity (ttm)	0 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	0
Qtrly Earnings Growth	0 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	0 (M)

PE Ratio	0
PEG Ratio	0
Price to Book value	0
Price to Sales	0
Price to Cash Flow	0

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.